AUTHORS
Florent Malard, MD, PhD, Maud Ngoya2, Giorgia Battipaglia3, Francis Ayuketang Ayuk, MD4, Stefania Bramanti5, Christof Scheid, MD6, Peter Dreger, Prof. Dr. med.7, Raynier Devillier, PhD8, Jakob Passweg, MD, MS9, Johannes Schetelig, MD,MSc10, Linde Morsink11, Ibrahim Yakoub-Agha, MD, PhD12, Judith Niederland, MD13, Arnon Nagler I, MD14, Katherine Clesham, MBBS, FRPATH15, Robert Zeiser, MD, PhD16, Emanuele Angelucci, MD17, Elisa Sala, MD, PhD18, Georg-Nikolaus Franke Sr, MD19, Ron Ram I, Head, BMT Unit20, Thomas Schroeder, MD21, Friedrich Stölzel22, Jurgen Kuball, MD23, Annalisa Ruggeri24, Ali Bazarbachi, MD, PhD25
AFFILIATIONS
1 Hôpital Saint-Antoine, Paris, France, Sorbonne Université, Paris, France
2 The EBMT, Barcelona, Spain
3 University of Naples Federico II, Napoli, Italy
4 University Medical Center Hamburg Eppendorf, Hamburg, Germany
5 Istituto Clinico Humanitas, Rozzano, Italy
6 University of Cologne, Köln, Germany
7 University of Heidelberg, Heidelberg, Germany
8 Institut Paoli-Calmettes, Marseille, France
9 Universität Basel, Basel, Switzerland
10 Universitaetsklinikum Dresden, Dresden, Germany
11 Universitair Medisch Centrum Groningen, Groningen, Netherlands
12 Chu Lille, Loos, France
13 HELIOS Klinikum Berlin-Buch, Berlin, Germany
14 Chaim Sheba Medical Center, Tel HaShomer, Israel
15 University College London Hospital, London, United Kingdom
16 University of Freiburg, Freiburg im Breisgau, Germany
17 IRCCS Ospedale Policlinico San Martino, Genova, Italy
18 University Hospital of Ulm, Ulm, Germany
19 Medical Clinic and Policinic 1, Leipzig, Leipzig, Germany
20 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
21 Essen University Hospital, Essen, Germany
22 University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
23 University Medical Center Utrecht, Utrecht, Netherlands
24 San Raffaele Hospital, Milano, Italy
25 American University of Beirut Medical Center, Ras Beyrouth, Lebanon
ABSTRACT
Introduction.
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated safety and efficacy in relapsed or refractory large B-cell lymphoma (R/R-LBCL). Nevertheless, a significant proportion of LBCL experience further relapse after CAR T-cells. In those patients, despite bispecific monoclonal antibodies are a valuable option, additional consolidation therapies are often discussed, including allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed outcomes of patients with LBCL that underwent allo-HCT for relapse after anti-CD19 CAR-T cells.
Patients and methods
We conducted a retrospective analysis using data from the European Group for Blood and Marrow Transplantation (EBMT) registry on behalf of the Lymphoma Working Party and the Cellular Therapy and Immunobiology Working Party. Included were 302 adult patients (70.5% males, 29.5% females) who underwent CAR-T -cell treatment between 2018 and 2024 for R/R-LBCL and then received an allo-HCT after experiencing further disease relapse .
Results
The majority of patients had a diffuse large B-cell lymphoma (n=266, 88.1%), while 27 patients had a Primary mediastinal large B-cell lymphoma (8.9%), 8 patients had T-cell/histiocyte-rich LBCL (2.6%) and one patient had a Primary LBCL of immune-privileged sites (0.3%). Median age at transplant was 54 (range 18-75) years. Previous auto-HCT was registered in 77 (25.5%) patients. Disease status at allo-HCT was complete remission (CR) in 136 (47.2%), partial remission (PR) in 77 (26.7%), relapse/progression in 52 (18.1%), stable disease in 20 (6.9%), missing in the remaining 17 patients. Median year of allo-HCT was 2022. Unrelated donors were more frequently used (57% of cases) followed by haploidentical (21.9%) and matched related siblings (21.2%). Peripheral blood was the preferred stem cell source in the majority of cases (95.4%). A Karnofsky performance status <90 was observed in 33.5% of patients while 28.4% presented with an HCT comorbidity index ≥3. A reduced-intensity conditioning regimen was used in 64% of cases. Total body irradiation was used in 27.8% of cases and 40.1% of patients received post-transplant cyclophosphamide. The cumulative incidence of absolute neutrophil count recovery at day 30 was 95.9% (95%CI, 92.1 - 97.9) and the cumulative incidence of platelet recovery above 20 G/L was 80.7% (95%CI, 75.3 - 85.1) at day 30 and 91.3% (95%CI, 87.1 - 94.2) at day 60.
With a median follow-up of 1.9 years, 2-year overall survival (OS) was 46.8% (95% CI, 40.2 - 53.1) and 2-year progression-free survival (PFS) was 37.2 (95% CI, 30.2 - 44.3). The cumulative incidence of relapse and non-relapse mortality were 38.9% (95% CI, 32 - 45.7) and 23.9% (95% CI, 18.1 - 30.1), respectively.
The day-100 cumulative incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) were 39.9% (95%CI, 3.1 - 46.6) and 18.5% (95%CI, 13.2 - 24.4) respectively. The 2-year cumulative incidence of overall and extensive chronic GVHD were 26.8% (95%CI, 20.2 - 33.7) and 6.7% (95%CI, 3.4 - 11.7), respectively. In multivariate analysis, disease status at allo-HCT (CR as reference) was independently associated to PFS (HR compared to PR: 2.92, 95% CI 1.52-5.62, p-value <0.001; HR compared to other disease status: 2.72, 95% CI 1.44-5.14, p-value 0.002), OS(HR compared to PR: 1.77, 95% CI 0.97-3.21, with a trend to statistical significance, p-value 0.06; HR compared to other disease status: 2.84, 95% CI 1.63-4.97, p-value <0.001)) and relapse (HR compared to PR: 3.15, 95% CI 1.35-7.32, p-value 0.008; HR compared to other disease status: 3.93, 95% CI 1.76-8.77, p-value <0.001).
Conclusion
This large EBMT registry study provides preliminary data that allo-HCT remains a feasible and potentially curative strategy for selected patients with LBCL relapsing after anti-CD19 CAR T-cell therapy, allowing durable disease control with acceptable toxicity. The advantage of allo-HCT seems more pronounced in patients with CR at time of allo-HCT. These results establish a contemporary benchmark for allo-HCT in the post-CAR T era and support its potential integration into the therapeutic algorithm for eligible patients. Further analysis to better identify which patients may benefit from the procedure is warranted.
DISCLOSURES
Florent Malard, MD, PhD: Amgen - Honoraria; Orcabio - Honoraria; Clinigen - Honoraria; BMS - Honoraria; Clinigen - Honoraria; Sanofi - Honoraria; MSD - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Pfizer - Honoraria; Astrazeneca - Honoraria; BMS - Honoraria; Priothera - Honoraria; Therakos - Honoraria; Sanofi - Honoraria; Astrazeneca - Honoraria; Therakos - Honoraria; Novartis - Honoraria; Priothera - Honoraria; Orcabio - Honoraria